



## RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research.

When NAMI learns of new studies by physicians and other scientists involving new treatment methods, such as psychotherapies, medications, methods of medication delivery, etc. we become excited. That excitement comes from knowing that scientists continue to learn more about mental illness and look for ways to improve the lives of those affected by it. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and National Director of Research and Quality Assurance Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](http://NAMI.org/research) or email us at [research@nami.org](mailto:research@nami.org).

## WHAT IS THE STUDY?

This study is a clinical trial to assess the safety and efficacy of an investigational drug, NV-5138, in adults with treatment-resistant depression. Participants will be randomly assigned to receive either: one of two doses of NV-5138, or a placebo. Participation requires a 9-week time commitment. Per completed visit, participants will be compensated \$51-\$125 depending on the study site. The goal of this study is to increase treatment options available to individuals who have not responded to previous antidepressant medications.

## WHO CAN PARTICIPATE?

Individuals may be eligible for this study if they:

- Are 18 to 70 years old
- Have a diagnosis of Major Depressive Disorder (MDD) without psychotic features
- Have tried 1-4 different medications for their depression without significant improvement in symptoms
- Have been on a stable therapeutic dose of antidepressant medication for at least 2 weeks prior to screening

*Note: Additional inclusion and exclusion criteria apply.*

The researchers are seeking 200 participants for this study.

## WHERE IS THE STUDY TAKING PLACE?

This is a national study taking place at sites in the following states: Washington, California, Missouri, Texas, Massachusetts, Vermont, Georgia, North Carolina, New Hampshire, Florida, New York, Utah, Pennsylvania, Tennessee, and Illinois.

## HOW DO I LEARN MORE?

The attached documents have additional information about the study. If you have questions or would like more information, please contact Nicole Alleyne at [nalleyne@supernus.com](mailto:nalleyne@supernus.com) or 240-403-5789.